Promising Clinical Trials in Neurodegenerative Diseases

Promising Clinical Trials in Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Promising Clinical Trials in Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Promising Clinical Trials in Neurodegenerative Diseases</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Overview

Promising Clinical Trials in Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Promising Clinical Trials in Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Promising Clinical Trials in Neurodegenerative Diseases</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Overview

This page summarizes notable ongoing and recent clinical trials for Alzheimer's disease, Parkinson's disease, ALS, frontotemporal dementia, Huntington's disease, and other neurodegenerative conditions. These trials represent the most advanced disease-modifying and neuroprotective approaches in the field. [@van2023]

Alzheimer's Disease

Disease-Modifying Therapies

Lecanemab (Leqembi)

• Target: Amyloid-beta protofibrils
• Phase: FDA Approved (2023)
• Company: Eisai/Biogen
• Mechanism: Monoclonal antibody targeting [Aβ](/proteins/amyloid-beta) protofibrils
• Status: First disease-modifying therapy with Phase 3 success
• Trial: CLARITY-AD (NCT03887455)
• Results: 27% slowing of clinical decline (CDR-SB)
• Key Findings: Significant reduction in amyloid PET centiloids, slowed [tau](/proteins/tau) accumulation
• Safety: ARIA-E (brain edema) in 12.6%, ARIA-H (microhemorrhages) in 17.3%

Donanemab (Kisunla)

• Target: N3pG [amyloid-beta](/proteins/amyloid-beta) plaques
• Phase: FDA Approved (2024)
• Company: Eli Lilly
• Trial: TRAILBLAZER-ALZ 2 (NCT04437511)
• Results: 35% slowing of decline in patients with low-to-medium tau
• Key Findings: Amyloid clearance achieved in majority of patients
• Safety: ARIA-E in 24% of patients, three deaths related to ARIA

Simufilam (CT1812)

• Target: Amyloid-beta oligomer antagonist
• Company: Cognition Therapeutics
• Phase: Phase 2/3
• Trial: NCT04932265 (SEQUEL)
• Mechanism: Prevents Aβ oligomer binding to synaptic receptors
• Status: Ongoing, results expected 2026

Blarcamesine (ANAVEX2-73)

• Target: Sigma-1 receptor agonist
• Company: Anavex
• Phase: Phase 2/3
• Trial: NCT03790709 (ANAVEX)
• Mechanism: Sigma-1 receptor activation promotes neuroprotection, reduces ER stress
• Status: Results pending, early signals showed cognitive improvement

Immunotherapy Approaches

ACI-35.40 (Lipid-based Tau Vaccine)

• Target: Phospho-tau (Ser396/404)
• Company: AC Immune/Janssen
• Phase: Phase 1b/2a
• Status: Safety and immunogenicity demonstrated
• Mechanism: Lipid nanoparticle delivery of phospho-tau antigens

ABBV-8E12 (Tilavonemab)

• Target: [Tau](/proteins/tau) protein
• Company: AbbVie
• Phase: Phase 2 (ABB-RD-02)
• Trial: NCT03712787
• Status: Ongoing

Semorinemab

• Target: Tau antibody
• Company: Genentech/Roche
• Phase: Phase 2 (LAURIET)
• Results: Did not meet primary endpoint in mild cognitive impairment

Neuroprotective Approaches

Lithium Carbonate

• Target: [GSK-3β](/entities/gsk3-beta) inhibition
• Phase: Phase 2/3
• Trials: NCT00088387, NCT02068560
• Status: Mixed results, ongoing studies in responders

Variglcit (Varoglit)

• Target: AMPK activator
• Company: Vivoryon
• Phase: Phase 2
• Mechanism: Activates AMPK, reduces tau phosphorylation
• Status: Completed, signals of cognitive benefit

Parkinson's Disease

Disease-Modifying Therapies

BIIB122 (DNL151)

• Target: LRRK2 kinase inhibitor
• Company: Biogen/Denali
• Phase: Phase 2b (LUMA)
• Trial: NCT05348785
• Status: Recruiting
• Rationale: LRRK2 mutations are common in familial PD, kinase hyperactivity in sporadic PD

AAV2-AADC (VY-AADC01)

• Target: Gene therapy for aromatic L-amino acid decarboxylase
• Company: Voyager Therapeutics
• Phase: Phase 1/2
• Trial: NCT03562494
• Status: Long-term benefits observed up to 5 years
• Mechanism: Restores dopamine synthesis in putamen

Prasinezumab (RO7046015)

• Target: [Alpha-synuclein](/proteins/alpha-synuclein) antibody
• Company: Roche
• Phase: Phase 2 (PASADENA)
• Results: Primary endpoint not met, follow-up showed slowing of motor progression

Cinpanemab (BIIB054)

• Target: Alpha-synuclein antibody
• Company: Biogen
• Phase: Phase 2 (SPARK)
• Results: Did not meet primary endpoint

Neuroprotective and Symptomatic

Inosine (SURE-PD3)

• Target: Urate elevation
• Phase: Phase 3
• Status: Primary endpoint not met, post-hoc analysis showed benefit in higher urate

Azilect (rasagiline)

• Target: MAO-B inhibition
• Phase: Phase 4
• Status: Disease-modifying signals in post-hoc analysis (ADAGIO)

Ampreloxetine (TD-9855)

• Target: Norepinephrine transporter inhibitor
• Company: Theravance
• Phase: Phase 3 (STEP-HF)
• Status: Orthostatic hypotension in PD

Amyotrophic Lateral Sclerosis

Approved Therapies

Tofersen (Qalsody)

• Target: SOD1 gene/mRNA
• Company: Biogen/Ionis
• Status: FDA approved 2023
• Trial: VALOR (NCT02623699) and open-label extension
• Results: Reduced SOD1 protein, slowed functional decline in SOD1 patients
• Mechanism: Antisense oligonucleotide reducing SOD1 production

Relyvrio (Albrioza/Sodium phenylbutyrate-taurursodiol)

• Target: Mitochondrial dysfunction and ER stress
• Company: Amylyx
• Status: FDA approved 2022 (withdrawn 2024)
• Trial: CENTAUR (NCT03021501)
• Results: Survival benefit, slower functional decline
• Note: Voluntarily withdrawn from market in 2024 after Phase 3 failure

In Development

CNM-Au8 (Gold nanocrystals)

• Target: Catalase mimetic, mitochondrial function
• Company: Clene Nanomedicine
• Phase: Phase 2/3 (HEALEY ALS Platform Trial)
• Status: Ongoing
• Results: Survival signal in preliminary analysis

Reldeso (ATXN2 ASO)

• Target: ATXN2 gene silencing
• Company: Biogen/Ionis
• Phase: Phase 1/2
• Rationale: ATXN2 intermediate repeats increase ALS risk

Mesenchymal Stem Cells

• Target: Neuroprotection, immunomodulation
• Phase: Various trials ongoing
• Company: Various

Gene Therapy Approaches

• AAV9-SOD1: Gene silencing for SOD1 ALS
• AAV9-FUS: Gene silencing for FUS ALS
• Antisense oligonucleotides: Multiple targets in development

Frontotemporal Dementia

Progranulin Modulators

AL001 (Litifilimab)

• Target: Progranulin modulator
• Company: Alector
• Phase: Phase 2/3 (INFRONT-2)
• Trial: NCT03987295
• Status: Received Fast Track designation
• Rationale: Progranulin deficiency causes ~10-20% of FTD

Tau-Targeted Therapies

ABBV-8E12 (Tilavonemab)

• Target: Tau antibody
• Company: AbbVie
• Phase: Phase 2
• Trial: NCT03712787

JNJ-63733657

• Target: Tau antibody
• Company: Janssen
• Phase: Phase 1
• Status: Completed

Huntington's Disease

Huntingtin-Lowering Approaches

Tominersen (RG6049)

• Target: [Huntingtin](/proteins/huntingtin-protein) mRNA
• Company: Roche/Ionis
• Phase: Phase 3 (GENERATION HD1)
• Status: Trial discontinued (negative results at high dose)
• New Approach: Lower-dose trial (GENERATION HD2) planned

other ASOs in Development

• Wave Life Sciences: Allele-selective ASOs targeting mutant [huntingtin](/genes/htt)
• PTC518: Oral ASO in development

Neuroprotective Approaches

Pridopidine

• Target: Sigma-1 receptor agonist
• Company: Prilenia
• Phase: Phase 2/3 (PROOF-HD)
• Status: Mixed results, signal in functional measures

VX-809 (Lumacaftor)

• Target: CFTR corrector (protein folding)
• Company: Vertex
• Rationale: May help mutant huntingtin folding
• Status: Phase 1

Biomarker Trials and Endpoints

Tau PET Imaging

• Tracers: Flortaucipir (AV-1451), MK-6240, PI-2620
• Use: Assessing tau burden as surrogate endpoint
• Correlation: Strong correlation with clinical outcomes in AD

Neurofilament Light Chain (NfL)

• Utility: Blood biomarker for disease progression
• Use: Used in multiple trial endpoints
• Platforms: Simoa, Elecsys
• Clinical utility: FDA cleared for ALS progression monitoring

CSF Biomarkers

• Aβ42/tau ratios: Amyloid and tau pathology
• Alpha-synuclein seeding assays: Syn-SAA for PD/DLB
• p-tau/t-tau ratio: Emerging for AD staging
• Emerging: Extracellular vesicles, neuronal damage markers

Genetic Biomarkers

• [APOE](/proteins/apoe-protein) status: Response prediction for anti-amyloid therapies
• LRRK2 G2019S: PD patient selection
• SOD1, FUS, [C9orf72](/entities/c9orf72): ALS genetic stratification

Trial Design Innovations

Master Protocols and Platform Trials

• HEALEY ALS Platform Trial: Multiple agents simultaneously
• [DIAN](/entities/dian-study): Adaptive trial in dominantly inherited AD
• Parkinson's Progression Markers Initiative (PPMI): Observational with trial-ready cohort

Digital Endpoints

• Remote monitoring: Continuous data collection
• Wearable devices: Motor symptom tracking
• [App](/entities/app-protein)-based cognitive testing: Ecological momentary assessment
• Voice analysis: Speech markers for progression

Adaptive Designs

• Sample size re-estimation: Interim adjustments
• Enrichment strategies: Biomarker-based patient selection
• Multi-arm designs: Efficient comparison of multiple doses

Regulatory Innovations

• Accelerated Approval: Based on surrogate endpoints
• Real-world evidence: Post-marketing requirements
• Patient-reported outcomes: Increased regulatory acceptance

Future Directions

Combination Therapies

• Rationale: Multiple pathological mechanisms require multi-target approaches
• Examples: Anti-amyloid + anti-tau, neuroprotection + disease modification
• Challenges: Regulatory pathways, safety considerations

Precision Medicine Approaches

• Genetic stratification: Population-specific responses
• Biomarker-guided: Patient selection based on pathology
• Digital phenotyping: Individualized monitoring

Prevention Trials

• Preclinical AD: Anti-amyloid in cognitively normal but biomarker-positive
• Genetic at-risk: CARMEL (autosomal dominant AD), Generation programs

Background

The study of Promising Clinical Trials In Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@sims2023]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [@miller2023]

Additional evidence sources: [@paganoni2024] [@scheltens2024] [@kwon2024] [@petrov2024] [@cummings2024] [@clinicaltrialsgov2026]

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Clinical Trials Index](/content/clinical-trials)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Lecanemab](/clinical-trials/lecanemab-clarity-ad)
• [Donanemab](/clinical-trials/nct05738486)
• [Tofersen](/therapeutics/tofersen)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov)
• [Alzheimer's Association TrialMatch](https://www.alz.org/)
• [Parkinson's Foundation Clinical Trials](https://www.parkinson.org/)
• [ALS Clinical Trials](https://www.als.net/)
• [CHDI Foundation - Huntington's Disease](https://www.chdi-foundation.org/)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypothesis/h-a20e0cbb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: APOE
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypothesis/h-44195347) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: APOE
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides](/hypothesis/h-b948c32c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: APOE, LRP1, LDLR
• [Competitive APOE4 Domain Stabilization Peptides](/hypothesis/h-d0a564e8) — <span style="color:#ffd54f;font-weight:600">0.51</span> · Target: APOE
• [Interfacial Lipid Mimetics to Disrupt Domain Interaction](/hypothesis/h-99b4e2d2) — <span style="color:#ffd54f;font-weight:600">0.46</span> · Target: APOE
• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1

Related Analyses:

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;